In type 2 diabetes, physicians have the opportunity to initiate cardioprotective glucose-lowering agents, such as glucagon-like peptide-1 receptor agonists or sodium-glucose cotransporter-2 inhibitors, after MI to reduce subsequent cardiovascular events [43]. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.